Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2016, Article ID 7963540, 7 pages
http://dx.doi.org/10.1155/2016/7963540
Review Article

PPARγ in Bacterial Infections: A Friend or Foe?

1Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
2Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA

Received 25 May 2016; Accepted 21 August 2016

Academic Editor: Paul D. Drew

Copyright © 2016 Aravind T. Reddy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. E. Almeida, A. B. Carneiro, A. R. Silva, and P. T. Bozza, “PPARγ expression and function in mycobacterial infection: roles in lipid metabolism, immunity, and bacterial killing,” PPAR Research, vol. 2012, Article ID 383829, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. B. Clark, “The role of PPARs in inflammation and immunity,” Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002. View at Google Scholar · View at Scopus
  3. B. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, no. 1, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Fajas, J.-C. Fruchart, and J. Auwerx, “PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter,” FEBS Letters, vol. 438, no. 1-2, pp. 55–60, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Li, J. Zhang, F. J. Schopfer et al., “Molecular recognition of nitrated fatty acids by PPARγ,” Nature Structural & Molecular Biology, vol. 15, no. 8, pp. 865–867, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. L. Feinstein, A. Spagnolo, C. Akar et al., “Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?” Biochemical Pharmacology, vol. 70, no. 2, pp. 177–188, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. L. M. S. Baker, P. R. S. Baker, F. Golin-Bisello et al., “Nitro-fatty acid reaction with glutathione and cysteine. Kinetic analysis of thiol alkylation by a Michael addition reaction,” The Journal of Biological Chemistry, vol. 282, no. 42, pp. 31085–31093, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. T. Reddy, S. P. Lakshmi, R. R. Muchumarri, and R. C. Reddy, “Nitrated fatty acids reverse cigarette smoke-induced alveolar macrophage activation and inhibit protease activity via electrophilic S-alkylation,” PLoS ONE, vol. 11, no. 4, Article ID e0153336, 2016. View at Publisher · View at Google Scholar
  11. U. Panchapakesan, C. A. Pollock, and X. M. Chen, “The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells,” American Journal of Physiology-Renal Physiology, vol. 287, no. 3, pp. F528–F534, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. S. P. Lakshmi, A. T. Reddy, Y. Zhang et al., “Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD),” The Journal of Biological Chemistry, vol. 289, no. 10, pp. 6383–6393, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. M. V. Schmidt, B. Brüne, and A. Von Knethen, “The nuclear hormone receptor PPARγ as a therapeutic target in major diseases,” TheScientificWorldJOURNAL, vol. 10, pp. 2181–2197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Croasdell, P. F. Duffney, N. Kim, S. H. Lacy, P. J. Sime, and R. P. Phipps, “PPARγ and the innate immune system mediate the resolution of inflammation,” PPAR Research, vol. 2015, Article ID 549691, 20 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Kaplan and B. Zingarelli, “Novel therapeutic agents in pediatric sepsis: peroxisome proliferator receptor γ (PPAR γ) agonists,” The Open Inflammation Journal, vol. 4, no. 1, pp. 120–124, 2011. View at Publisher · View at Google Scholar
  16. F. C. Tenover, “Mechanisms of antimicrobial resistance in bacteria,” The American Journal of Medicine, vol. 119, no. 6, pp. S3–S10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. M. Aronoff, C. H. Serezani, J. K. Carstens et al., “Stimulatory effects of peroxisome proliferator-activated receptor-γ on Fcγ receptor-mediated phagocytosis by alveolar macrophages,” PPAR Research, vol. 2007, Article ID 52546, 8 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Asada, S. Sasaki, T. Suda, K. Chida, and H. Nakamura, “Antiinflammatory roles of peroxisome proliferator-activated receptor γ in human alveolar macrophages,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 2, pp. 195–200, 2004. View at Google Scholar
  19. A. T. Reddy, S. P. Lakshmi, S. Dornadula, S. Pinni, D. R. Rampa, and R. C. Reddy, “The nitrated fatty acid 10-nitro-oleate attenuates allergic airway disease,” The Journal of Immunology, vol. 191, no. 5, pp. 2053–2063, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. E. Stegenga, S. Florquin, A. F. de Vos, and T. van der Poll, “The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice,” Critical Care Medicine, vol. 37, no. 2, pp. 614–618, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Kielian, M. M. Syed, S. Liu et al., “The synthetic peroxisome proliferator-activated receptor-γ agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses,” The Journal of Immunology, vol. 180, no. 7, pp. 5004–5016, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Fernandez-Boyanapalli, S. C. Frasch, D. W. H. Riches, R. W. Vandivier, P. M. Henson, and D. L. Bratton, “PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease,” Blood, vol. 116, no. 22, pp. 4512–4522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. F. Fernandez-Boyanapalli, E. L. Falcone, C. S. Zerbe et al., “Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment,” Journal of Allergy and Clinical Immunology, vol. 136, no. 5, pp. 1399.e3–1401.e3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. R. F. Fernandez-Boyanapalli, S. C. Frasch, S. M. Thomas et al., “Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease,” Journal of Allergy and Clinical Immunology, vol. 135, no. 2, pp. 517–527.e12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Migliavacca, A. Assanelli, F. Ferrua et al., “Pioglitazone as a novel therapeutic approach in chronic granulomatous disease,” The Journal of Allergy and Clinical Immunology, vol. 137, no. 6, pp. 1913–1915.e2, 2016. View at Publisher · View at Google Scholar
  26. A. T. Reddy, S. P. Lakshmi, J. M. Kleinhenz, R. L. Sutliff, C. M. Hart, and R. C. Reddy, “Endothelial cell peroxisome proliferator-activated receptor γ reduces endotoxemic pulmonary inflammation and injury,” The Journal of Immunology, vol. 189, no. 11, pp. 5411–5420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Zingarelli, M. Sheehan, P. W. Hake, M. O'Connor, A. Denenberg, and J. A. Cook, “Peroxisome proliferator activator receptor-γ ligands, 15-deoxy-Δ12,14-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways,” The Journal of Immunology, vol. 171, no. 12, pp. 6827–6837, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ogawa, J. Lozach, C. Benner et al., “Molecular determinants of crosstalk between nuclear receptors and toll-like receptors,” Cell, vol. 122, no. 5, pp. 707–721, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. B. M. Necela, W. Su, and E. A. Thompson, “Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor γ and nuclear factor-κB in macrophages,” Immunology, vol. 125, no. 3, pp. 344–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. E. Ferreira, F. Sisti, F. Sônego et al., “PPAR-γ/IL-10 axis inhibits MyD88 expression and ameliorates murine polymicrobial sepsis,” The Journal of Immunology, vol. 192, no. 5, pp. 2357–2365, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. H. S. Warren, “Peroxisome proliferator-activated receptor-gamma agonists, control of bacterial outgrowth, and inflammation,” Critical Care Medicine, vol. 37, no. 2, pp. 773–774, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. R. C. Reddy, “Immunomodulatory role of PPAR-gamma in alveolar macrophages,” Journal of Investigative Medicine, vol. 56, no. 2, pp. 522–527, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. E. L. Gautier, A. Chow, R. Spanbroek et al., “Systemic analysis of PPARγ in mouse macrophage populations reveals marked diversity in expression with critical roles in resolution of inflammation and airway immunity,” The Journal of Immunology, vol. 189, no. 5, pp. 2614–2624, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Kelly, J. I. Campbell, T. P. King et al., “Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shutting of PPAR-γ and RelA,” Nature Immunology, vol. 5, no. 1, pp. 104–112, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. A. M. Bodles, V. Varma, A. Yao-Borengasser et al., “Pioglitazone induces apoptosis of macrophages in human adipose tissue,” Journal of Lipid Research, vol. 47, no. 9, pp. 2080–2088, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. Y.-C. Chen, S.-C. Shen, and S.-H. Tsai, “Prostaglandin D2 and J2 induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1743, no. 3, pp. 291–304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Padilla, K. Kaur, H. J. Cao, T. J. Smith, and R. P. Phipps, “Peroxisome proliferator activator receptor-γ agonists and 15-deoxy-Δ12,14-PGJ2 induce apoptosis in normal and malignant B-lineage cells,” The Journal of Immunology, vol. 165, no. 12, pp. 6941–6948, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Padilla, E. Leung, and R. P. Phipps, “Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists,” Clinical Immunology, vol. 103, no. 1, pp. 22–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Tautenhahn, B. Brüne, and A. von Knethen, “Activation-induced PPARγ expression sensitizes primary human T cells toward apoptosis,” Journal of Leukocyte Biology, vol. 73, no. 5, pp. 665–672, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Soller, A. Tautenhahn, B. Brüne et al., “Peroxisome proliferator-activated receptor γ contributes to T lymphocyte apoptosis during sepsis,” Journal of Leukocyte Biology, vol. 79, no. 1, pp. 235–243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. M. V. Schmidt, P. Paulus, A.-M. Kuhn et al., “Peroxisome proliferator-activated receptor γ-induced T cell apoptosis reduces survival during polymicrobial sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 1, pp. 64–74, 2011. View at Publisher · View at Google Scholar
  42. R. C. Reddy, V. R. Narala, V. G. Keshamouni, J. E. Milam, M. W. Newstead, and T. J. Standiford, “Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-γ,” Blood, vol. 112, no. 10, pp. 4250–4258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. H. Napimoga, S. M. Vieira, D. Dal-Secco et al., “Peroxisome proliferator-activated receptor-γ ligand, 15-deoxy-Δ12,14-prostaglandin J2, reduces neutrophil migration via a nitric oxide pathway,” The Journal of Immunology, vol. 180, no. 1, pp. 609–617, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. K.-I. Inoue, H. Takano, R. Yanagisawa et al., “Effect of 15-deoxy-Δ12,14-prostaglandin J2 on acute lung injury induced by lipopolysaccharide in mice,” European Journal of Pharmacology, vol. 481, no. 2-3, pp. 261–269, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. J. M. Kaplan, J. A. Cook, P. W. Hake, M. O'Connor, T. J. Burroughs, and B. Zingarelli, “15-Deoxy-Δ12,14-prostaglandin J2 (15D-PGJ2), a peroxisome proliferator activated receptor γ ligand, reduces tissue leukosequestration and mortality in endotoxic shock,” Shock, vol. 24, no. 1, pp. 59–65, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Liu, Z. Geng, W. Zhu, H. Wang, Y. Chen, and J. Liang, “15-deoxy-Delta(1)(2, (1)(4)-prostaglandin J(2) ameliorates endotoxin-induced acute lung injury in rats,” Chinese Medical Journal, vol. 127, no. 5, pp. 815–820, 2014. View at Google Scholar
  47. C. W. Philipson, J. Bassaganya-Riera, M. Viladomiu et al., “The role of peroxisome proliferator-activated receptor γ in immune responses to enteroaggregative escherichia coli infection,” PLoS ONE, vol. 8, no. 2, Article ID e57812, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. P. E. Almeida, A. R. Silva, C. M. Maya-Monteiro et al., “Mycobacterium bovis bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-activated receptor γ expression and activation: functions in inflammation, lipid metabolism, and pathogenesis,” The Journal of Immunology, vol. 183, no. 2, pp. 1337–1345, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. H. D'Avila, R. C. N. Melo, G. G. Parreira, E. Werneck-Barroso, H. C. Castro-Faria-Neto, and P. T. Bozza, “Mycobacterium bovis bacillus Calmette-Guérin induces TLR2-mediated formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo,” The Journal of Immunology, vol. 176, no. 5, pp. 3087–3097, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. K. A. Mattos, H. D'Avila, L. S. Rodrigues et al., “Lipid droplet formation in leprosy: toll-like receptor-regulated organelles involved in eicosanoid formation and Mycobacterium leprae pathogenesis,” Journal of Leukocyte Biology, vol. 87, no. 3, pp. 371–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. K. A. Mattos, V. G. C. Oliveira, H. D'Avila et al., “TLR6-driven lipid droplets in Mycobacterium leprae-infected Schwann cells: immunoinflammatory platforms associated with bacterial persistence,” The Journal of Immunology, vol. 187, no. 5, pp. 2548–2558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Singh, Y. K. Loke, and C. D. Furberg, “Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis,” Thorax, vol. 66, no. 5, pp. 383–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Christaki, P. Anyfanti, and S. M. Opal, “Immunomodulatory therapy for sepsis: an update,” Expert Review of Anti-Infective Therapy, vol. 9, no. 11, pp. 1013–1033, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. L.-A. Pirofski and A. Casadevall, “Immunomodulators as an antimicrobial tool,” Current Opinion in Microbiology, vol. 9, no. 5, pp. 489–495, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. H. D. Volk, P. Reinke, and W. D. Döcke, “Clinical aspects: from systemic inflammation to ‘immunoparalysis’,” Chemical Immunology, vol. 74, pp. 162–177, 2000. View at Google Scholar
  56. S. C. A. Meijvis, E. M. W. van de Garde, G. T. Rijkers, and W. J. W. Bos, “Treatment with anti-inflammatory drugs in community-acquired pneumonia,” Journal of Internal Medicine, vol. 272, no. 1, pp. 25–35, 2012. View at Publisher · View at Google Scholar · View at Scopus